• Active, not recruiting

NCT01729091: Phase 2: Umbilical Cord Blood-Derived NK Cells, Elotuzumab, Len, Melphalan f/b ASCT

Updated: Jun 15

NCT01729091: Phase 2: Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma


umbilical cord nk cells

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma


This phase II trial studies the side effects and best dose of umbilical cord blood-derived natural killer cells when given together with elotuzumab, lenalidomide, and high dose melphalan before autologous stem cell transplant and to see how well they work in treating patients with multiple myeloma. Before transplant, stem cells are taken from patients and stored. Immunotherapy with monoclonal antibodies, such as elotuzumab, may induce changes in the body's immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide and melphalan, may work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving natural killer cells from donor umbilical cord blood before transplant may also kill myeloma cells that remain in the body after the last chemotherapy treatment. After treatment, stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.


Sponsor

M.D. Anderson Cancer Center


Collaborator

National Cancer Institute (NCI)

 

ClinicalTrials.gov Identifier: NCT01729091


Official Title: Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma


First Posted: November 20, 2012


Click here to see details on ClinicalTrials.gov

 

Procedure: Autologous Hematopoietic Stem Cell Transplantation

Biological: Elotuzumab

Other: Laboratory Biomarker Analysis

Drug: Lenalidomide

Drug: Melphalan

Biological: Natural Killer Cell Therapy

Biological: Umbilical Cord Blood-Derived Lymphocyte Therapy

 

Meeting: 2022 ASCO Annual Meeting - Session Type: Clinical Science Symposium - Session Title:

Beating Bad Blood: The Power of Immunotherapy in Hematologic Malignancies - Track: Hematologic Malignancies, Hematologic Malignancies - Sub Track: Hematologic Malignancies - Clinical Trial Registration Number: NCT01729091

Abstract#: 8009 - Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM)


Click here to read abstract details

 

ABSTRACTS & PRESENTATIONS

2022 ASCO ANNUAL MEETING - June 3-7, 2022 - McCormick Place, Chicago, IL - Hybrid Meeting

2022 ASCO Annual Meeting - Oral Abstract Session

Click here for details

 

Location

United States, Texas


Posts Archive